Trials / Recruiting
RecruitingNCT06487455
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
An Open, Multicenter, Dose-escalation, and Dose-expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SPH7485 Tablets in Patients With Advanced Solid Tumors.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH7485 | SPH7485： Orally, once daily, 50-400mg, 21 days per cycle |
Timeline
- Start date
- 2024-08-06
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2024-07-05
- Last updated
- 2025-08-17
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06487455. Inclusion in this directory is not an endorsement.